The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
Open accessAbstract
Community-onset (CO) candidemia, defined as a positive blood culture taken at or within 2 days of hospital admission, represents a distinct clinical entity associated with substantial morbidity and mortality. Reference MIC results from the SENTRY Antimicrobial Surveillance Program (2008-2009) were analyzed to compare the antifungal resistance patterns and species distributions from patients with CO and nosocomial bloodstream infections (BSI) in 79 medical centers. Among 1,354 episodes of BSI, 494 (36.5%) were classified as CO and 860 (63.5%) as nosocomial in origin. More than 95% of the isolates from both BSI types were contributed by Candida albicans (48.4%), C. glabrata (18.2%), C. parapsilosis (17.1%), C. tropicalis (10.6%), and C. krusei (2.0%). C. albicans was more common in CO BSI (51.0%) than nosocomial BSI (46.9%), whereas C. parapsilosis and C. krusei were more common in nosocomial BSIs (18.1 and 2.7%, respectively) than in CO BSIs (15.4 and 0.8%, respectively). C. glabrata and C. tropicalis were comparable in both CO (18.4 and 10.5%, respectively) and nosocomial (18.1 and 10.6%, respectively) episodes. Resistance to azoles (fluconazole, posaconazole, and voriconazole) and echinocandins (anidulafungin, caspofungin, and micafungin) was uncommon (<5%) in CO BSI using recently established Clinical and Laboratory Standards Institute breakpoint criteria. Resistance to echinocandins (anidulafungin [3.8%], caspofungin [5.1%], and micafungin [3.2%]) and azoles (fluconazole [7.7%], posaconazole [5.1%], and voriconazole [6.4%]) was most prevalent among nosocomial BSI isolates of C. glabrata . CO candidemia is not uncommon and appears to be increasing worldwide due to changing health care practices. Although resistance to the azoles and echinocandins remains uncommon among CO isolates, we demonstrate the emergence of nosocomial occurrences of C. glabrata expressing resistance to both monitored classes of antifungal agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Species and drug- resistance patterns are known to vary substantially by geography, facility, and even among units within the same facility [24, 25].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With respect to CLSI clinical breakpoints, fluconazole resistance, defined as MIC values ≥8 mg/L for C. albicans, has been reported overall to be as high as 3.5%.43–48”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Second, the increased incidence of invasive candidiasis caused by non-albicans Candida (NAC) species, such as Candida glabrata, Candida tropicalis, Candida krusei or Candida parapsilosis, has been a major concern [13], [14], because these infections are often associated with higher mortality and antifungal resistance than those caused by C. albicans [15], [16].”
From In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections (2014) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Although much of the literature concerning IC has focused on nosocomial (NOS) bloodstream infections (BSI), especially those occurring in the intensive care unit (ICU) (3, 12, 13, 25, 27, 49), an increasing incidence of IC overall (35, 50), combined with data from the National Nosocomial Infection System survey, which…”
ResultSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Weinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“It is now evident that a delay in initiating antifungal therapy in the critically ill patient is associated with compromised outcomes (an increase in mortality of 8% for each hour in which appropriate therapy is delayed), excessive costs of hospitalization, and potentially devastating complications such as endocarditi…”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Self-citationEpidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610
Antifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Cinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 345
The Candida Pathogenic Species Complex
Turner, S. A., & Butler, G. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019778 · Cited by 336
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
Emerging fungal infections in immunocompromised patients
Low, C.-Y., & Rotstein, C. (2011) · F1000 Medicine Reports · doi:10.3410/m3-14 · Cited by 309
Wisplinghoff, H., Ebbers, J., Geurtz, L., Stefanik, D., Major, Y., Edmond, M. B., Wenzel, R. P., & Seifert, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.005 · Cited by 293
“9%), whilst not consistent with clinical experience, compares with other recent studies [2,16].”
BackgroundResultInfluentialMcCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
Healey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276
Epidemiology of candidaemia and invasive candidiasis. A changing face
Quindós, G. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.10.001 · Cited by 219
Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214
Potential Use of Phenolic Acids as Anti-Candida Agents: A Review
Teodoro, G. R., Ellepola, K., Seneviratne, C. J., & Koga-Ito, C. Y. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01420 · Cited by 204
Candida auris: Disinfectants and Implications for Infection Control
Ku, T. S. N., Walraven, C. J., & Lee, S. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00726 · Cited by 177
FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174
Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis
Pfaller, M. A., & Castanheira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv076 · Cited by 161
Self-citationAuberger, J., Lass‐Flörl, C., Aigner, M., Clausen, J., Gastl, G. A., & Nachbaur, D. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks189 · Cited by 156
Peixoto, L. R., Rosalen, P. L., Ferreira, G. L. S., Freires, I. A., de Carvalho, F. G., Castellano, L. R. C., & de Castro, R. D. (2016) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2016.10.013 · Cited by 142
SAFDAR, A. Y. E. S. H. A., & Armstrong, D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir492 · Cited by 137
Orasch, C., Marchetti, O., Garbino, J., Schrenzel, J., Zimmerli, S., Mühlethaler, K., Pfyffer, G. E., Ruef, C., Fehr, J. S., Zbinden, R., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12440 · Cited by 134
Mesa-Arango, A. C., Forastiero, A., Bernal‐Martínez, L., Cuenca‐Estrella, M., Mellado, E., & Zaragoza, Ó. (2012) · Medical Mycology · doi:10.3109/13693786.2012.737031 · Cited by 136
Azole Resistance in Dermatophytes
Ghannoum, M. A. (2015) · Journal of the American Podiatric Medical Association · doi:10.7547/14-109 · Cited by 113
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
Procópio, T. F., Patriota, L. L. D. S., de Moura, M. C., da Silva, P. M., de Oliveira, A. P. S., Carvalho, L. V. D. N., Lima, T. D. A., Soares, T., da Silva, T. D., Coelho, L. C. B. B., et al. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.02.019 · Cited by 108
In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Wong, S. S. W., Kao, R. Y. T., Yuen, K. Y., Wang, Y., Yang, D., Samaranayake, L. P., & Seneviratne, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085836 · Cited by 107
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 122
Nishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Chen, Y.-L., Konieczka, J. H., Springer, D. J., Bowen, S. E., Zhang, J., Silao, F. G. S., Bungay, A. A. C., Bigol, U. G., Nicolas, M. G., Abraham, S. N., et al. (2012) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.112.002279 · Cited by 97
Genetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93
Epidemiology and antifungal resistance in invasive candidiasis
Rodloff, A., Koch, D., & Schaumann, R. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-187 · Cited by 90
Lindberg, E., Hammarström, H., Ataollahy, N., & Kondori, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-40280-8 · Cited by 87
Pryszcz, L. P., Németh, T., Gácser, A., & Gabaldón, T. (2013) · Genome Biology and Evolution · doi:10.1093/gbe/evt185 · Cited by 87
Acquired multidrug antifungal resistance in Candida lusitaniae during therapy
Asner, S. A., Giulieri, S., Diezi, M., Marchetti, O., & Sanglard, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-15 · Cited by 82
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Antifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
“Resistant mutants can pre-exist with variable frequency between the susceptible clones, and in the course of infection and therapeutic treatment they can overcome the susceptible clones, representing the main cause of the therapeutic failure [3–6].”
BackgroundJensen, R. H., Johansen, H. K., Søes, L. M., Lemming, L. E., Rosenvinge, F. S., Nielsen, L., Olesen, B., Kristensen, L., Dzajic, E., Astvad, K. M. T., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01763-15 · Cited by 77
Cinnamaldehyde incorporated gellan/PVA electrospun nanofibers for eradicating Candida biofilm
Mishra, P., Gupta, P., & Pruthi, V. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111450 · Cited by 81
Schell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01817-16 · Cited by 74
“5 1 2 4 8 16 32 64 128 VT-1129 —b — — 3 (1) 8c (6) 10 (7) 8 (7) 5 (5) — — — — — — VT-1161 — — 1 5c (1) 13 (12) 5 (4) 8 (7) 2 (2) — — — — — — FLC — — — — — 1 2 (1) 6c (2) 9 (8) 4 (4) 2 (1) 4 (4) 2 (1) 4 (4) VRC 1 — 5 (2) 12c (9) 4 (4) 3 (2) 4 (4) 3 (3) 2 (2) — — — — — ANF — — 3 (2) 3 (2) 7 (6) 1 (1) 3 7 (7) 5 (4) 5c (4…”
Coping with Stress and the Emergence of Multidrug Resistance in Fungi
Shor, E., & Perlin, D. S. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004668 · Cited by 76
Antifungal Application of Nonantifungal Drugs
Stylianou, M., Kulesskiy, E., Lopes, J. P., Granlund, M., Wennerberg, K., & Urban, C. F. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01087-13 · Cited by 74
Wüthrich, M., Brandhorst, T. T., Sullivan, T. D., Filutowicz, H. I., Sterkel, A., Stewart, D. A., Li, M., Lerksuthirat, T., LeBert, V., Shen, Z. T., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.02.009 · Cited by 70
Ploidy dynamics and evolvability in fungi
Wertheimer, N. B., Stone, N. R. H., & Berman, J. G. (2016) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2015.0461 · Cited by 87
Lackner, M., Tscherner, M., Schaller, M., Kuchler, K., Mair, C., Sartori, B., Istel, F., Arendrup, M. C., & Lass-Flörl, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00123-14 · Cited by 67
Candidaemia in Sweden: a nationwide prospective observational survey
Ericsson, J., Chryssanthou, E., Klingspor, L., Johansson, A. G., Ljungman, P. T., Svensson, E., & Sjölin, J. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12111 · Cited by 67
Farooqi, J. Q., Jabeen, K., Saeed, N., Iqbal, N. J., Malik, B., Lockhart, S. R., Zafar, A., Brandt, M. E., & Hasan, R. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.048785-0 · Cited by 70
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02120-10 · Cited by 63
Self-citationSiopi, M., Tarpatzi, A., Kalogeropoulou, E., Damianidou, S., Vasilakopoulou, A., Vourli, S., Pournaras, S., & Meletiadis, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01516-19 · Cited by 63
Vella, A., Carolis, E. D., Mello, E., Perlin, D. S., Sanglard, D., Sanguinetti, M., & Posteraro, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-09329-4 · Cited by 64
de Melo, A. P. V., Zuza-Alves, D. L., Rocha, W. P. D. S., de Souza, L. B. F. C., Francisco, E. C., Melo, A. S. D. A., & Chaves, G. M. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.02.002 · Cited by 62
Lohmann, C., Sabou, M., Moussaoui, W., Prévost, G., Delarbre, J.-M., Candolfi, E., Gravet, A., & Letscher‐Bru, V. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.03268-12 · Cited by 67
The Economic Impact of Rapid Candida Species Identification by T2Candida Among High-Risk Patients
Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015) · Future Microbiology · doi:10.2217/fmb.15.29 · Cited by 58
Self-citationIn vitro antifungal activity of silver nanoparticles against fluconazole-resistant Candida species
Bonilla, J. J. A., Guerrero, D. J. P., Sánchez, C. I., López, C. C. O., & Torres, R. G. (2015) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-015-1933-z · Cited by 58
Risk factors predicting Candida infective endocarditis in patients with candidemia
Foong, K. S., Sung, A., Burnham, J. P., Kronen, R., Lian, Q., Zetina, A. S., Hsueh, K., Lin, C., Powderly, W. G., & Spec, A. (2019) · Medical Mycology · doi:10.1093/mmy/myz104 · Cited by 57
Asadzadeh, M., Ahmad, S., Hagen, F., Meis, J. F. G. M., Al‐Sweih, N., & Khan, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142880 · Cited by 54
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Rasheed, M., Battu, A., & Kaur, R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.813741 · Cited by 51
Delfino, D., Scordino, F., Pernice, I., Passo, C. L., Galbo, R., David, A., Barberi, I., Criseo, G., Cascio, A., & Romeo, O. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12685 · Cited by 56
Klotz, U., Schmidt, D., Willinger, B., Steinmann, E., Buer, J., Rath, P., & Steinmann, J. (2016) · Mycoses · doi:10.1111/myc.12472 · Cited by 55
Al-Baqsami, Z. F., Ahmad, S., & Khan, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-63240-z · Cited by 54
Mishra, P., Gupta, P., Srivastava, A., Poluri, K. M., & Prasad, R. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121163 · Cited by 51
Parslow, B. Y., & Thornton, C. R. (2022) · Microorganisms · doi:10.3390/microorganisms10061208 · Cited by 57
Candida glabrata susceptibility to antifungals and phagocytosis is modulated by acetate
Mota, S., Alves, R., Carneiro, C., Silva, S., Brown, A. J., Istel, F., Kuchler, K., Sampaio, P., Casal, M., Henriques, M., et al. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00919 · Cited by 49
Identification and typing of the Candida parapsilosis complex: MALDI-TOF MS vs. AFLP
Carolis, E. D., Hensgens, L. A. M., Vella, A., Posteraro, B., Sanguinetti, M., Senesi, S., & Tavanti, A. (2014) · Medical Mycology · doi:10.1093/mmy/myt009 · Cited by 49
Xisto, M. I. D. D. S., Caramalho, R., Rocha, D. A. S., Ferreira‐Pereira, A., Sartori, B., Barreto‐Bergter, E., Junqueira, M. L., Lass‐Flörl, C., & Lackner, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw558 · Cited by 46
Anti-fungal susceptibility and virulence factors of Candida spp. isolated from blood cultures
Sriphannam, C., Nuanmuang, N., Saengsawang, K., Amornthipayawong, D., & Kummasook, A. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.08.001 · Cited by 46
Rosato, A., Catalano, A. A., Carocci, A., Carrieri, A., Carone, A., Caggiano, G., Franchini, C., Corbo, F., & Montagna, M. T. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.026 · Cited by 47
An Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2013) · Infection · doi:10.1007/s15010-013-0558-0 · Cited by 49
Astuti, S. D., Puspita, P. S., Putra, A. P., Zaidan, A. H., Fahmi, M. Z., Syahrom, A., & Suhariningsih, S. (2018) · Lasers in Medical Science · doi:10.1007/s10103-018-2677-4 · Cited by 42
Antifungal susceptibility profiles of rare ascomycetous yeasts
Hansen, A. P., Lass‐Flörl, C., Lackner, M., Rare Yeast Study Group, Aigner, M., Alastruey‐Izquierdo, A., Arıkan-Akdağlı, S., Bader, O., Becker, K., Boekhout, T., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz231 · Cited by 43
Alkharashi, N., AlJohani, S. M., Layqah, L. A., Masuadi, E., Baharoon, W., Al-Jahdali, H. H., & Baharoon, S. A. (2019) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2019/2015692 · Cited by 50
Eddouzi, J., Lohberger, A., Vogne, C., Manaï, M., & Sanglard, D. (2013) · Medical Mycology · doi:10.3109/13693786.2013.800239 · Cited by 48
Chromatin-mediated Candida albicans virulence
da Rosa, J. L., & Kaufman, P. D. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.08.007 · Cited by 43
Risk factors and clinical analysis of candidemia in very-low-birth-weight neonates
Fu, J., Wang, X., Wei, B., Jiang, Y., & Chen, J. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.03.026 · Cited by 39
Navarathna, D. H. M. L. P., Pathirana, R. U., Lionakis, M. S., Nickerson, K. W., & Roberts, D. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164449 · Cited by 34
Lepak, A. J., Zhao, M., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-19 · Cited by 34
Reda, N. M., Hassan, R. M., Salem, S. T., & Yousef, R. (2022) · Infection · doi:10.1007/s15010-022-01888-7 · Cited by 40
Candida africana: Is It a Fungal Pathogen?
Romeo, O., Tietz, H.-J., & Criseo, G. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0142-1 · Cited by 31
Nanoemulsion as an Effective Treatment against Human-Pathogenic Fungi
Garcia, A., Fan, Y. Y., Vellanki, S., Huh, E. Y., Vanegas, D., Wang, S. H., & Lee, S. C. (2019) · mSphere · doi:10.1128/msphere.00729-19 · Cited by 33
Erum, R., Samad, F., Khan, A., & Kazmi, S. U. (2020) · BMC Microbiology · doi:10.1186/s12866-020-02045-6 · Cited by 31
Endemic Genotypes of Candida albicans Causing Fungemia Are Frequent in the Hospital
Escribano, P., Rodríguez‐Créixems, M., Sánchez‐Carrillo, C., Muñóz, P., Bouza, E., & Guinea, J. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00516-13 · Cited by 36
Specific pathways mediating inflammasome activation by Candida parapsilosis
Tóth, A., Zajta, E., Csonka, K., Vágvölgyi, C., Netea, M. G., & Gácser, A. (2017) · Scientific Reports · doi:10.1038/srep43129 · Cited by 33
Experimental Biofilm-Related Candida Infections
Cirasola, D., Sciota, R., Vizzini, L., Ricucci, V., Morace, G., & Borghi, E. (2013) · Future Microbiology · doi:10.2217/fmb.13.36 · Cited by 36
Epidemiology of Echinocandin Resistance in Candida
Grossman, N. T., Chiller, T. M., & Lockhart, S. R. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0209-7 · Cited by 33
Feglo, P. K. (2012) · British Microbiology Research Journal · doi:10.9734/bmrj/2012/861 · Cited by 36
Juárez‐Cepeda, J., Orta‐Zavalza, E., Cañas‐Villamar, I., Arreola, J., Pérez-Cornejo, G. P., Hernández-Carballo, C. Y., Gutiérrez‐Escobedo, G., Castaño, I., & Peñas, A. D. L. (2015) · Current Genetics · doi:10.1007/s00294-015-0473-2 · Cited by 30
Nagy, I., Filkor, K., Németh, T., Hamari, Z., Vágvölgyi, C., & Gácser, A. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-122 · Cited by 28
Usher, J., & Haynes, K. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008259 · Cited by 27
“glabrata infections has grown rapidly over the last 20 years, and is responsible for ~25% of systemic candidiasis cases [14,15].”
BackgroundWillaert, R., Kayacan, Y., & Devreese, B. V. (2021) · Pathogens · doi:10.3390/pathogens10111397 · Cited by 27
Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia
Eschenauer, G. A., Nguyen, M.-H., & Clancy, C. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015590838 · Cited by 27
Liu, W., Lai, C., Li, M.-C., Wu, C.-J., Ko, W., Hung, Y.-L., Tang, H.-J., & Hsueh, P. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.08.007 · Cited by 30
Simor, A. E., Porter, V. R., Mubareka, S., Chouinard, M., Katz, K. C., Vermeiren, C. L., Fattouh, R., Matukas, L. M., Tadros, M., Mazzulli, T., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01387-18 · Cited by 27
Paolucci, M., Foschi, C., Tamburini, M. V., Ambretti, S., Lazzarotto, T., & Landini, M. P. (2014) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2014.06.018 · Cited by 26
Paluchowska, P., Tokarczyk, M., Bogusz, B., Skiba‐Kurek, I., & Budak, A. (2014) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-0276140099 · Cited by 25
Candidaemia in the non-neutropenic patient: A critique of the guidelines
Deshpande, A., Gaur, S., & Bal, A. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.005 · Cited by 26
Gaona-Flores, V. A., Campos-Navarro, L. A., Cervantes-Tovar, R. M., & Alcalá-Martínez, E. (2016) · Medical Mycology · doi:10.1093/mmy/myw017 · Cited by 26
Moreno-García, E., Puerta‐Alcalde, P., Gariup, G., Fernández‐Ruiz, M., López-Cortés, L. E., Cuervo, G., Salavert, M., Merino, P., Machado, M., Guinea, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab250 · Cited by 25
Ylipalosaari, P., Ala-Kokko, T. I., Karhu, J., Koskela, M., Laurila, J., Ohtonen, P. P., & Syrjälä, H. (2012) · Critical Care · doi:10.1186/cc11307 · Cited by 29
Surveillance study of candidemia in cancer patients in North China
Li, D., Zhang, W., Zheng, S., Ma, Z., Zhang, P., & Liu, Z. (2012) · Medical Mycology · doi:10.3109/13693786.2012.727481 · Cited by 23
Metadata
- Authors
- Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M.
- Affiliations
- JMI Laboratories (US)
- Tufts University (US)
- Corresponding author
- Castanheira, Mariana
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 561-566
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3028787
- OpenAlex
- W2103765663
- Cited by
- 238
- References
- 49
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 7 · 2019: 25 · 2018: 11 · 2017: 18 · 2016: 24 · 2015: 24 · 2014: 20 · 2013: 20 · 2012: 20
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidemia, nosocomial bloodstream infection, Candida species distribution, antifungal resistance, echinocandin resistance, azole resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida krusei, SENTRY Antimicrobial Surveillance Program, MIC breakpoints, fluconazole
- MeSH terms
- Antifungal Agents, Azoles, Candida, Candidiasis, Cross Infection, Humans, Microbial Sensitivity Tests, Population Surveillance, Species Specificity, Global Health, Community-Acquired Infections, Drug Resistance, Fungal, Echinocandins, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.